-
The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer
28 Mar 2024 13:57 GMT
… treatment has made great progress through the unremitting efforts of medical and pharmaceutical … 1:200 (Santa Cruz Biotechnology, Santa Cruz, USA … assists in predicting drug responses and validating … infiltration after neoadjuvant paclitaxel followed by FEC …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… Peters, chair of the medical oncology and thoracic malignancies … nearly 200 clinical trials evaluating more than 36 … paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment … ; the impact of pharmaceutical industry regulation and health …
-
Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia
27 Mar 2024 13:30 GMT
… trial has received regulatory approval from the US FDA … is a biotechnology company that develops antibody-based treatments for life … multiple clinical trials; the phase I/IIa trial CANFOUR, … PDAC (gemcitabine/nab-paclitaxel) or NSCLC (platinum-based …
-
Her2+ Gastric Cancer Market Report 2032: Epidemiology, Pipeline Therapies, Latest FDA, EMA Approvals by DelveInsight
27 Mar 2024 11:32 GMT
… market outlook, drug uptake, treatment scenario and epidemiology … Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine … drugs (such as cisplatin or oxaliplatin), and taxanes (such as paclitaxel …
-
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
26 Mar 2024 23:38 GMT
… decreased weight. In clinical trials, adverse reactions were managed … plus nab-paclitaxel as a first-line treatment in patients … new drugs to address diseases with high unmet medical … third parties.
Information about pharmaceutical products (including products …
-
Bile Duct Cancer Market Analysis 2032: Epidemiology Forecast, Therapies, FDA Approvals and Companies by DelveInsight
26 Mar 2024 14:21 GMT
… current treatment practices, emerging drugs, the … Forma Therapeutics, Basilea Pharmaceutica, Celgene, Bristol Myer … (lenvatinib), ZANIDATAMAB, Nab-paclitaxel, LONSURF (Trifluridine and … Duct Cancer Treatment Algorithm, Current Treatment, and Medical Practices
…
-
FDA Grants ODD to Utidelone Capsules For Treatment of Gastric Cancer
25 Mar 2024 19:16 GMT
… Pharmaceuticals) has been granted orphan drug designation (ODD) for the treatment of … and paclitaxel plus encequidar (Oraxol; Kinex Pharmaceuticals, Hanmi Pharmaceuticals)—in clinical trials as … -stage phase 2 clinical trial which assessed the safety and …
-
Ovarian cancer: four drug trials to watch
25 Mar 2024 15:22 GMT
… respond to treatment.
There are several trials investigating … for the seven major pharmaceutical markets (7MM: US … Unit at Rambam Medical Center in Israel. … trial of its flagship drug Keytruda (pembrolizumab), in combination with carboplatin/paclitaxel …
-
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer
28 Mar 2024 20:39 GMT
… from a phase 2 trial (NCT03093155) presented at … of Maryland Medical System in Baltimore.
The trial was designed … investigator-initiated, open-label trial enrolled patients 18 years … within 6 months of treatment with paclitaxel/docetaxel administration …
-
Ivonescimab/Chemo Shows Promising Anti-Tumor Activity in NSCLC Subsets
26 Mar 2024 20:35 GMT
… Additionally, grade 3 or higher treatment-related adverse effects (TRAEs) … from the AK112-201 trial, specifically data concerning patients … group or ivonescimab plus paclitaxel at 175 mg… across 4 phase 3 trials. These trials include HARMONi (NCT05184712), …